# A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)

> **NCT05133518** · PHASE2 · COMPLETED · sponsor: **Melt Pharmaceuticals** · enrollment: 338 (actual)

## Conditions studied

- Cataract

## Interventions

- **DRUG:** MELT-300
- **DRUG:** Midazolam alone
- **DRUG:** Ketamine alone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05133518
- **Lead sponsor:** Melt Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-20
- **Primary completion:** 2022-10-26
- **Final completion:** 2022-11-03
- **Target enrollment:** 338 (ACTUAL)
- **Last updated:** 2022-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05133518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05133518, "A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05133518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*